Spero Therapeutics
SPRO
53 hedge funds and large institutions have $113M invested in Spero Therapeutics in 2018 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 6 reducing their positions, and 5 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 6
180% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 5
20% more funds holding
Funds holding: 44 → 53 (+9)
2.69% more ownership
Funds ownership: 56.48% → 59.16% (+2.7%)
5% less capital invested
Capital invested by funds: $119M → $113M (-$6.14M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$10.4M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$5.1M |
| 3 |
AIC
AWM Investment Company
New York
|
+$4.64M |
| 4 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$4.44M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.84M |
Top Sellers
SPRO Hedge Fund Activity: Q3 2018 in Review
53 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q3 2018, worth a combined $113M — down 5.2% from $119M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new SPRO positions and 5 closed out — a net gain of 9 holders — while 24 added to existing stakes and 6 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $10.4M. The largest seller was RA Capital Management, exiting entirely with an estimated $10.9M sold.
- 53 institutional investors held Spero Therapeutics (SPRO) as of Q3 2018, up from 44 in Q2 2018.
- Funds reported $113M of Spero Therapeutics stock for Q3 2018, down 5.2% quarter-over-quarter.
- 14 funds opened new Spero Therapeutics positions in Q3 2018 and 5 closed out, a net change of +9 holders.
- The largest Spero Therapeutics buyer in Q3 2018 was EcoR1 Capital, an estimated $10.4M added.
- The largest Spero Therapeutics seller in Q3 2018 was RA Capital Management, an estimated $10.9M sold.
Based on aggregated 13F filings for Q3 2018.